Nov 7 (Reuters) - Canada’s Valeant Pharmaceuticals International Inc reported a 10.5 percent fall in quarterly revenue on Tuesday, hurt by declining sales in its branded drugs division.
Net income attributable to Valeant was $1.30 billion, or $3.69 per share, in the third quarter ended Sept. 30, compared with a loss of $1.22 billion, or $3.49 per share, a year earlier.
The reported quarter included a tax benefit of about $1.4 billion, the company said.
Total revenue fell to $2.22 billion from $2.48 billion. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)
Our Standards: The Thomson Reuters Trust Principles.